(UroToday.com) In conjunction with the Scientific Congress held as part of the American Society of Clinical Oncologys (ASCO) Annual Meeting in May 2020, an Educational Symposium was convened on August 8 to 10th. In a session entitled Sorting Through the Maze of Treatment Options for Metastatic Castration-Sensitive Prostate Cancer, Dr. Alicia Morgans from Northwestern University presented a plenary talk discussing the treatment considerations for patients who received combination therapy for metastatic castration sensitive prostate cancer (mCSPC). This followed prior presentations from Dr. Carmel Pezaro and Dr. Neal Shore regarding the role of chemotherapy and novel androgen axis inhibitors in patients with mCSPC.
Dr. Morgans began by highlighting that, as per National Comprehensive Cancer Network (NCCN) guidelines, combination therapy with androgen deprivation therapy and another agent (apalutamide, abiraterone, docetaxel, or enzalutamide) is recommended.
While there are a number of treatment options for patients with mCSPC, there is an even greater plethora of treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), with no less than seven different agents available on the basis of prior therapies received, patient characteristics, and tumor characteristics.
Clearly, prior lines of therapy (including those used in the mCSPC space) influence future treatment choices when the patient progresses to mCRPC. In the mCRPC disease space, treatment choices may be guided by the following factors, among others:
1. prior treatment received, with a preference for novel mechanisms of action2. treatment availability in practice setting/location3. presence of visceral metastasis or restriction to bone-only metastasis4. candidacy for chemotherapy, on the basis of patient comorbidity and frailty5. histologic characteristics, including the presence of small cell/neuroendocrine differentiation6. targetable genetic or genomic characteristics including actionable DNA damage repair mutations or presence of microsatellite instability high status7. availability of clinical trials
Dr. Morgans highlighted that resistance mechanisms can spread through metastasis-to-metastasis seeding and similar resistance patterns are often seen in geographic proximity suggesting an element of interclonal cooperativity. As a result, at the time of disease progression, the use of therapy with a novel treatment mechanism is necessary to counter to acquired resistance.
As a general principle, Dr. Morgans outlined that sequencing of androgen axis inhibitors (including abiraterone acetate, enzalutamide, apalutamide, and darolutamide) is generally poorly effective. To drive home this point, Dr. Morgans reviewed data from the CARD trial which randomized patients who had progression on one androgen axis targeting agent to a switch or to cabazitaxel. Only 14% of patients who switched to the other androgen axis targeting agent had a PSA response of 50% or more and median progression-free survival was only 2.7 months (95% confidence interval 2.4 to 2.8 months) in contrast to median progression-free survival of 4.4 months (95% confidence interval 3.6 to 5.4 months) among those randomized to cabazitaxel (hazard ratio 0.52, 95% confidence interval 0.40 to 0.68). Similarly, in PROfound, patients who had disease progression on a novel androgen axis inhibitor were randomized to physicians choice of therapy (often including a switch to another androgen axis inhibitor) or Olaparib. As with the CARD trial, patients randomized to a second androgen axis inhibitor had median progression-free survival of 3.55 months (hazard ratio 0.34, 95% confidence interval 0.25 to 0.47).
Apart from these randomized data, there are a number of other studies that have assessed response rates for sequencing of androgen axis targeting agents demonstrates generally short progression-free survival.
Dr. Morgans then highlighted data that may guide specific treatment considerations in particular populations. First, she reviewed data from the PROCEED observational registry of patients treated with sipuleucel-T. In a prostate-specific antigen (PSA) matched analysis, median overall survival was significantly longer for African American men (35.3 months) as compared to Caucasian men (25.8 months) (hazard ratio 0.70, 95% confidence interval 0.57 to 0.86). Further, baseline PSA at the time of initiating sipuleucel-T therapy was associated with survival patients with PSA below the median (29.5 ng/mL) had improved survival (hazard ratio 0.52, 95% confidence interval 0.37 to 0.72).
In an international early access program, observational data suggested that asymptomatic patients receiving radium-223 had significantly improved overall survival compared to those who were symptomatic at the initiation of therapy (hazard ratio 0.49, 95% confidence interval 0.33 to 0.73).
Beyond clinicodemographic factors, Dr. Morgans discussed genetic and genomically targeted approaches. She first examined data from TRITON2 in which patients with mCRPC and deleterious mutations in DNA defect repair (DDR) genes who had progressed on androgen axis targeting agents received rucaparib in a single-arm design. The vast preponderance of patients had a beneficial PSA response. Subsequently, the PROfound study reported a randomized comparison of Olaparib versus physicians choice among a similar patient population. They demonstrated significantly improved radiographic progression-free survival among those receiving olaparib (median 5.8 months) versus physicians choice of therapy (median 3.5 months; hazard ratio 0.49, 95% confidence interval 0.38 to 0.63). Great detail regarding the data for PARP inhibitors in prostate cancer is provided in a UroToday Center of Excellence article.
On the basis of these data, rucaparib has been approved for men with BRCA1/2 mutations who have progressed following androgen receptor-targeted therapy and taxane chemotherapy while olaparib has been approved for men with Homologous Recombination Repair (HRR) mutations following androgen receptor-targeted therapy, with or without prior taxane treatment.
Beyondpoly ADP ribose polymerase (PARP) inhibitors, pembrolizumab is another targeted option for men with advanced prostate cancer. In this case, patients must have microsatellite instability-high status to be eligible, as the United States Federal Drug Administration (FDA) has approved pembrolizumab in a tissue agnostic fashion for patients with microsatellite instability-high tumors. Dr. Morgans reported that approximately 2-3% of men with prostate cancer will have microsatellite instability-high tumors, and are therefore expected to have radiographic responses to pembrolizumab.
Dr. Morgans closed by highlighting the importance of shared decision making for patients with advanced prostate cancer. This is particularly important where there are so many treatment options. Patient preferences may be driven by home or work obligations, by past or vicarious experiences or fears, by insurance restrictions, and other factors.
Moving forward, Dr. Morgans highlighted the potential for theranostics, including the therapeutic role of Lutetium-177-prostate-specific membrane antigen (LuPSMA). A number of ongoing trials will assess the role of Lu-PSMA, including in a comparison against cabazitaxel in patients who have progressed following docetaxel and in comparison against best supportive or standard of care in patients who have progressed following both taxane chemotherapy and an androgen axis inhibitor.
Presented by: Alicia Morgans, MD, MPH, Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois
Written by:Christopher J.D. Wallis, Urologic Oncology Fellow, Vanderbilt University Medical Center,@WallisCJD on Twitteratthe ASCO20 Virtual Education Program, #ASCO20, August 8-10, 2020.
- Reducing barriers to mainstream gene therapy - BioPharma-Reporter.com - September 4th, 2020
- Mapping Genetic Diversity of Lung Tumors Over Time May Lead to More Effective Therapies - UCSF News Services - September 4th, 2020
- Multi-site study to evaluate the role of testing guidelines in ensuring access to genetic information for men with prostate cancer - PRNewswire - September 4th, 2020
- Global Prime Editing Market to Witness Heightened Growth During the Period 2020 2030 - The Daily Chronicle - September 4th, 2020
- Liquid biopsies to disrupt the oncology testing market - Medical Device Network - September 4th, 2020
- Global RNA-interference (RNAi) Market Growth, Trends and Forecasts to 2025: Focus on Key Players Alnylam Pharmaceuticals, Arrowhead, Quark... - September 4th, 2020
- Yale researchers find a cause and possible treatment for Fragile X - Yale News - September 4th, 2020
- 'Coming into their own': FDA approval of liquid biopsy tests puts early, less invasive cancer detection in broader reach - USA TODAY - September 4th, 2020
- Fusion Genes Associated With More Aggressive Papillary Thyroid Cancer in Pediatric Patients - Targeted Oncology - September 4th, 2020
- Existing Class of Drugs May Improve Neurological Function in Patients with Rare, Aggressive Genetic Disorder - Newswise - September 4th, 2020
- Genomic analysis reveals insights on virulent, emerging foodborne pathogen - UB Now: News and views for UB faculty and staff - University at Buffalo... - September 4th, 2020
- Hyperthyroidism is associated with breast cancer risk and mammographic and genetic risk predictors - 2 Minute Medicine - September 4th, 2020
- Health history platform launches to trace genetic conditions | Digital Healthcare - Healthcare Global - Healthcare News, Magazine and Website - September 4th, 2020
- New HIV Gene Therapy, CAR-T Treatments Could be on the Horizon for Patients - BioSpace - September 4th, 2020
- Cell Suicide Gene Further Linked to Immunotherapy Response - Technology Networks - September 2nd, 2020
- Genetic mutations may be linked to infertility, early menopause - Washington University School of Medicine in St. Louis - September 2nd, 2020
- How to use precision medicine to personalise COVID-19 treatment according to the patient's genes - Down To Earth Magazine - September 2nd, 2020
- UCT professors research offers hope of treatment for sickle cell anaemia - Daily Maverick - September 2nd, 2020
- Association of recent stressful life events with mental and physical health in the context of genomic and exposomic liability for schizophrenia - 2... - September 2nd, 2020
- Finding order in the chaos of cancer mutations - Drug Target Review - September 2nd, 2020
- Mustang Bio Announces Orphan Drug Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency in Newly Diagnosed Infants -... - September 2nd, 2020
- Novavax Announces Publication of Phase 1 Data for COVID-19 Vaccine Candidate in The New England Journal of Medicine - GlobeNewswire - September 2nd, 2020
- Department of Genetic Medicine | Johns Hopkins Medicine - August 10th, 2020
- Genetic Medicine | Internal Medicine | Michigan Medicine ... - August 10th, 2020
- Genetic Medicine | Department of Medicine - August 10th, 2020
- Genomics and Medicine - Genome.gov - August 10th, 2020
- New Approach to Treating Osteoarthritis Advances | NYU Langone News - NYU Langone Health - August 10th, 2020
- Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates - Business Wire - August 10th, 2020
- Here's Why Shares of Editas Medicine and Beam Therapeutics Are Soaring Today - Motley Fool - August 10th, 2020
- Grant will fund study into COVID outcome disparities in NYC - Cornell Chronicle - August 10th, 2020
- A versatile genetic control system in mammalian cells and mice responsive to clinically licensed sodium ferulate - Science Advances - August 10th, 2020
- Spark Therapeutics Deepens Drug Development Expertise in Hematology and Rare Disease with Appointment of Gallia G. Levy, MD, Ph.D., as Chief Medical... - August 10th, 2020
- Chromosomal Rearrangements Associated with Chemotherapeutic Drug Resistance | McDonnell Boehnen Hulbert & Berghoff LLP - JD Supra - August 10th, 2020
- Jae Jung, Ph.D., Appointed as Chair of Cleveland Clinic Lerner Research Institute's Department of Cancer Biology - Health Essentials from Cleveland... - August 10th, 2020
- The UK and TCELS to jointly support COVID-19 research in Thailand - GOV.UK - August 10th, 2020
- Akouos Announces Expansion of Executive Team and Board of Directors - BioSpace - August 10th, 2020
- Medical and neurobehavioural phenotypes in male and female carriers of Xp22.31 duplications in the UK Biobank. - Physician's Weekly - August 10th, 2020
- Coronavirus vaccine breakthrough: New generation cure that stops virus developed - Express - August 10th, 2020
- Global Cell and Gene Therapy Market, Forecast to 2025 by Product, Disease, End-user and Region - COVID-19 Updated - PRNewswire - August 10th, 2020
- Not Everyone Needs 8 Hours of Sleep, New Research Reveals | Time - TIME - August 10th, 2020
- Lindsey Criswell Named Director of National Institute of Arthritis and Musculoskeletal and Skin Diseases - UCSF News Services - August 10th, 2020
- Pinpointing The Cells That Keep The Bodys Master Circadian Clock Ticking - Newswise - August 10th, 2020
- Kazia Therapeutics hits A$1 on grant of Rare Pediatric Disease Designation to paxalisib for DIPG - Proactive Investors USA & Canada - August 10th, 2020
- Edited Transcript of PSNL.OQ earnings conference call or presentation 6-Aug-20 9:00pm GMT - Yahoo Finance - August 10th, 2020
- Ovid and Angelini partner on treating Angelman syndrome in Europe - Pharmaceutical Technology - August 10th, 2020
- Doctoral Student/Research Assistant in Mitochondrial Biology and Signalling job with UNIVERSITY OF HELSINKI | 218596 - Times Higher Education (THE) - August 10th, 2020
- Simpler COVID-19 test could provide results in hours from saliva - University of Wisconsin-Madison - August 10th, 2020
- This company has a better version of a simpler, faster Covid-19 test - STAT - August 7th, 2020
- Mental Notes: Music Cognition Lab is dedicated to the scientific study of how music affects the brain and behavior - Vanderbilt University News - August 6th, 2020
- Nasha Fitter Elected to Board of Directors of the ACMG Foundation for Genetic and Genomic Medicine - PRNewswire - August 5th, 2020
- HDAC6 Can Control Tumor Growth and Halt Metastasis in Triple-Negative Breast Cancer - Newswise - August 5th, 2020
- Will programming a cell ever be as easy as programming an app? - SynBioBeta - August 5th, 2020
- Penn Researchers Identify New Genetic Cause of a Form of Inherited Neuropathy - Newswise - August 5th, 2020
- Genetic Variant in Persons of African Descent Linked with Stroke: Analysis - DocWire News - August 5th, 2020
- Invitae Reports $46.2 Million in Revenue Driven by More Than 120000 Samples Accessioned in the Second Quarter of 2020 - Monterey County Weekly - August 5th, 2020
- Noel R. Rose, widely regarded as the father of autoimmune disease research, dies at 92 - The Hub at Johns Hopkins - August 5th, 2020
- Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis - GlobeNewswire - August 5th, 2020
- Seragon Announces GenomeScore, the First AI Platform to Measure Rate of Aging and Physiological Changes - PRNewswire - August 5th, 2020
- Vaccine 'durability': COVID-19 immunizations coming soon but will they last? - Genetic Literacy Project - August 5th, 2020
- Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for the Prevention and Treatment of... - August 5th, 2020
- Stoke Therapeutics to Present at Upcoming Investor Conferences in August - Business Wire - August 4th, 2020
- The global cell and gene therapy market by revenue is expected to grow at a CAGR of over 30.90% during the period 20192025 - GlobeNewswire - August 4th, 2020
- Cochlear implant uses LEDs to tackle hearing loss - Optics.org - August 4th, 2020
- Rozlytrek, Roche's first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with... - August 4th, 2020
- Alnylam Pharmaceuticals : Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis -... - August 4th, 2020
- 'The younger the child, the likelier to find causative gene of infant epilepsy' - Korea Biomedical Review - Korea Biomedical Review - August 3rd, 2020
- Known genes associated with male infertility doubled - BioNews - August 3rd, 2020
- Alnylam Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis (NASH) - Business... - August 3rd, 2020
- Cancer drug is first therapy to emerge from 23andMe-GSK deal - STAT - STAT - August 3rd, 2020
- Dr. Rana on the Rationale for Video Genetic Counseling in Prostate Cancer - OncLive - August 3rd, 2020
- Metastatic Lung Cancer Study Finds That Bionano's Saphyr Outperforms NGS for the Detection of Structural Variants - GlobeNewswire - August 3rd, 2020
- Health Media in the COVID-19 Era: A mid-wave report - Features - MM&M - Medical Marketing and Media - August 3rd, 2020
- Cyberpunk 2077 shows off the ruined dreams district of Pacifica in new concept art - Critical Hit - August 2nd, 2020
- An unsupported American conspiracy theory found a foothold in Europe. New research shows how - NewsDio - August 2nd, 2020
- Study Suggests New Approach to Improve Radiation Therapy Resistance in Glioblastoma - Michigan Medicine - August 1st, 2020
- Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis - BioSpace - August 1st, 2020
- Our Genes May Explain Severity of COVID-19 and Other Infections - Quanta Magazine - August 1st, 2020
- Omega Therapeutics Lands $85M to Tap Into Control Room of Biology - Xconomy - August 1st, 2020
- EarlyBird Study: Early Detection of Adult-Onset Type 2 Diabetes in Youth - Diabetes In Control - August 1st, 2020
- Movers & Shakers, July 24 | BioSpace - BioSpace - July 31st, 2020